Drug updated on 3/28/2024
| Dosage Form | Injection (intravenous: 4 mg) |
| Drug Class | Alkylating agents |
| Ongoing and Completed Studies | ClinicalTrials.gov |
Indication
- For the treatment of adult patients with metastatic small cell lung cancer (SCLC) with disease progression on or after platinum-based chemotherapy.
Summary
- Lurbinectedin (Zepzelca) is indicated for the treatment of adult patients with metastatic small cell lung cancer (SCLC) who have experienced disease progression on or after platinum-based chemotherapy.
- Two systematic reviews/meta-analyses were reviewed to gather information about Zepzelca's effectiveness and safety in treating SCLC.
- The first review highlighted a lack of promising investigational drugs/regimens in late-stage development, indicating that relapsed SCLC remains an area of high unmet need; however, it did not specifically discuss lurbinectedin's performance compared to other treatments.
- In contrast, the second review conducted a matching-adjusted indirect comparison between lurbinectedin and other second-line treatments for SCLC including oral and intravenous topotecan as well as platinum re-challenge therapy.
- This analysis found that among patients with platinum-sensitive SCLC, lurbinectedin demonstrated superior survival benefits along with a favorable safety profile when compared against these alternative therapies.
- Specifically, hazard ratios suggested significant overall survival benefit associated with lurbinectedin use versus oral topotecan (HR: 0.43), IV topotecan (HR: 0.43), and platinum re-challenge therapy (HR: 0.42).
Product Monograph / Prescribing Information
| Document Title | Year | Source |
|---|---|---|
| Zepzelca (lurbinectedin) Prescribing Information. | 2022 | Jazz Pharmaceuticals, Inc., Palo Alto, CA |
Systematic Reviews / Meta-Analyses
| Document Title | Year | Source |
|---|---|---|
| Clinical, pharmacoeconomic , and stakeholder input combined report. | 2023 | CADTH |
| Current and emerging treatment options for patients with relapsed small-cell lung carcinoma: a systematic literature review. | 2023 | Clinical Lung Cancer |
| Indirect treatment comparison of lurbinectedin versus other second-line treatments for small-cell lung cancer. | 2023 | Journal of comparative effectiveness research. |
Clinical Practice Guidelines
| Document Title | Year | Source |
|---|---|---|
| SEOM clinical guidelines for the treatment of small‑cell lung cancer (SCLC) (2019). | 2020 | Clinical and Translational Oncology |